Merck Could Plummet On FDA’s Warning For Propecia

Mercks Merck Could Plummet On FDAs Warning For PropeciaMany of us tend to be vain to an extent, and some of us worry about the way our appearances are perceived by others. It’s got more to do with our own insecurities than how our appearance makes a difference in our lives. Nonetheless, men and women find it difficult to stop focusing on changing texture of skin and thinning hair, both of which can cause a lot of concern among most people, if not everyone.

Talking about thinning hair, of particular importance is male pattern baldness, for which only two drugs are approved by the FDA: Minoxidil and Finasteride. Minoxidil is easily tolerated and with continued use, men tend to keep much of their hair, even if they can’t grow back what they have already lost. However, Finasteride is not tolerated well by many men and many discontinue taking it because of its side effects, most notably, sexual dysfunction.

Merck’s (MRK) hair loss drug Propecia will now begin to carry labels that warn users of potential sexual dysfunction even after the treatment is stopped. This could cause considerable damage to Merck, which has continuously maintained its position that Propecia is well tolerated among men. The argument goes that clear causal facts between Finasteride and sexual dysfunction or loss of libido have not been established.

Growing empirical evidence suggests that men may experience sexual dysfunction in terms of loss of libido, erectile dysfunction, reduced sperm quality and infertility even when they stop using Finasteride to fight hair loss.To continue reading, click here.

Leave a Comment